The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Open accessAbstract
BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma. METHODS: In this phase 2 study, we investigated oral ibrutinib, at a daily dose of 560 mg, in 111 patients with relapsed or refractory mantle-cell lymphoma. Patients were enrolled into two groups: those who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles of bortezomib or had received no prior bortezomib therapy. The primary end point was the overall response rate. Secondary end points were duration of response, progression-free survival, overall survival, and safety. RESULTS: The median age was 68 years, and 86% of patients had intermediate-risk or high-risk mantle-cell lymphoma according to clinical prognostic factors. Patients had received a median of three prior therapies. The most common treatment-related adverse events were mild or moderate diarrhea, fatigue, and nausea. Grade 3 or higher hematologic events were infrequent and included neutropenia (in 16% of patients), thrombocytopenia (in 11%), and anemia (in 10%). A response rate of 68% (75 patients) was observed, with a complete response rate of 21% and a partial response rate of 47%; prior treatment with bortezomib had no effect on the response rate. With an estimated median follow-up of 15.3 months, the estimated median response duration was 17.5 months (95% confidence interval [CI], 15.8 to not reached), the estimated median progression-free survival was 13.9 months (95% CI, 7.0 to not reached), and the median overall survival was not reached. The estimated rate of overall survival was 58% at 18 months. CONCLUSIONS: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01236391.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, it is not selective for BTK, and multiple mechanisms of resistance, including the C481S-BTK mutation, can compromise its efficacy.”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
In the citing paper
“often due to the C481S mutation of BTK, which prevents ibrutinib from forming a covalent bond with BTK and significantly reduces its potency, resulting in median progression-free survival of only ;14 months.8”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
In the citing paper
“often due to the C481S mutation of BTK, which prevents ibrutinib from forming a covalent bond with BTK and significantly reduces its potency, resulting in median progression-free survival of only ;14 months.8”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,236
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Self-citationOptimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
The Non-Hodgkin's Lymphoma Classification Project (1997) · Blood · doi:10.1182/blood.v89.11.3909 · Cited by 2,456
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Self-citationChronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,651
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128
Self-citationHerman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- 10.2307/2281868 · DOI · Paper page
Cited by
Sorted by citations
Items 701–800 of 1,000
Elmachkouri, Y. A., Irrou, E., Ouachtak, H., Zaki, M. E. A., Gomha, S. M., Oubella, A., Alotaibi, S. H., & Taha, M. L. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.142829 · Cited by 18
Ibrutinib for the treatment of Waldenström macroglobulinemia
Chakraborty, R., Kapoor, P., Ansell, S. M., & Gertz, M. A. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1061427 · Cited by 18
Maddocks, K. J., & Blum, K. A. (2014) · Current Treatment Options in Oncology · doi:10.1007/s11864-014-0274-8 · Cited by 18
Self-citationIbrutinib‐associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma
Furtado, M., Wang, M. L., Munneke, B., McGreivy, J. S., Beaupre, D. M., & Rule, S. A. (2015) · British Journal of Haematology · doi:10.1111/bjh.13275 · Cited by 18
Self-citationCurrent regimens and novel agents for mantle cell lymphoma
Chen, Y., Wang, M. L., & Romaguera, J. E. (2014) · British Journal of Haematology · doi:10.1111/bjh.13000 · Cited by 18
Self-citationClinical Insights Into the Biology and Treatment of Pancreatic Cancer
Mettu, N. B., & Abbruzzese, J. L. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2015.009092 · Cited by 18
Discovery of Pyrazolopyrimidine Derivatives as Novel Dual Inhibitors of BTK and PI3Kδ
Pujala, B., Agarwal, A. K., Middya, S., Banerjee, M., Surya, A., Nayak, A. K., Gupta, A., Khare, S., Guguloth, R., Randive, N. A., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00356 · Cited by 18
Distinct and Overlapping Functions of TEC Kinase and BTK in B Cell Receptor Signaling
de Bruijn, M. J. W., Rip, J., van der Ploeg, E. K., van Greuningen, L. W., Ta, V. T. B., Kil, L. P., Langerak, A. W., Rimmelzwaan, G. F., Ellmeier, W., Hendriks, R. W., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601285 · Cited by 18
Sandoval-Sus, J. D., Sotomayor, E. M., & Shah, B. D. (2017) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2017.02.003 · Cited by 18
Vidal‐Crespo, A., Rodríguez, V., Matas‐Céspedes, A., Lee‐Vergés, E., Rivas‐Delgado, A., Giné, E., Navarro, A., Beà, S., Campo, E., López‐Guillermo, A., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.168930 · Cited by 18
Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma
Maeda, A., Nishida, Y., Weetall, M. L., Cao, L., Branstrom, A. A., Ishizawa, J., Nii, T., Schober, W. D., Abe, Y., Matsue, K., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25558 · Cited by 18
Targeting Wnt signaling pseudokinases in hematological cancers
Karvonen, H., Perttilä, R., Niininen, W., Barker, H. R., & Ungureanu, D. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13137 · Cited by 18
Caldwell, R. D., Liu‐Bujalski, L., Qiu, H., Mochalkin, I., Jones, R. C., Neagu, C., Goutopoulos, A., Grenningloh, R., Johnson, T. L., Sherer, B., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.09.033 · Cited by 18
Kabadi, S., Near, A. M., Wada, K., & Burudpakdee, C. (2019) · Cancer Medicine · doi:10.1002/cam4.2559 · Cited by 18
Sathyanarayanan, V., Flowers, C. R., & Iyer, S. P. (2020) · JCO Global Oncology · doi:10.1200/go.20.00012 · Cited by 18
Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice
Pieters, T., T’Sas, S., Vanhee, S., Almeida, A., Driege, Y., Roels, J., Loocke, W. V., Daneels, W., Baens, M., Marchand, A., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20202280 · Cited by 21
Some important inhibitors and mechanisms of rheumatoid arthritis
Zhou, S., & Huang, G. (2021) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14015 · Cited by 18
Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)
Tbakhi, B., & Reagan, P. M. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221080738 · Cited by 18
A Systematic Review of Treatments of Relapsed/Refractory Mantle Cell Lymphoma
Parrott, M., Rule, S. A., Kelleher, M., & Wilson, J. S. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.10.004 · Cited by 18
Self-citationShah, N. N., Colina, A. S., Johnson, B. D., Szabó, A., Furqan, F., Kearl, T. J., Schneider, D., Vargas-Cortes, M., Schmeling, J. L., Dwinell, M. B., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02158 · Cited by 17
Wu, S., Cao, W., Fu, S., Yao, B., Yang, Z., Yin, C., Mishra, V., Addison, D., Zhang, P., & Wang, D. (2025) · CHI Conference on Human Factors in Computing Systems · doi:10.1145/3706598.3714272 · Cited by 22
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches
Eyre, T. A., Cheah, C. Y., Sarkozy, C., Kumar, A. A., & Gouill, S. L. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00146 · Cited by 18
Speed bumps on the road to a chemotherapy-free world for lymphoma patients
Cheson, B. D. (2016) · Blood · doi:10.1182/blood-2016-04-709477 · Cited by 17
Liang, J., Ren, Y., Du, K., Gao, R., Duan, Z., Guo, J., Xing, T., Wang, W., Wang, L., Wang, Y., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.18878 · Cited by 17
BTKi-induced cardiovascular toxicity in CLL: Risk mitigation and management strategies
Kozarac, S., Vuković, V., Fradley, M. G., & Antic, D. A. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101268 · Cited by 17
Drug‐Induced Liver Injury Associated With Emerging Cancer Therapies
Chodup, P., Samodelov, S. L., Visentin, M., & Kullak-Ublick, G. A. (2025) · Liver International · doi:10.1111/liv.70002 · Cited by 16
Do mantle cell lymphomas have an ‘Achilles heel’?
Saba, N. S., & Wiestner, A. U. (2014) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000057 · Cited by 17
Ibrutinib: a paradigm shift in management of CLL
Badar, T., Burger, J. A., Wierda, W. G., & O'Brien, S. M. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.977862 · Cited by 17
B-cell receptor pathway modulators in NHL
Blum, K. A. (2015) · Hematology · doi:10.1182/asheducation-2015.1.82 · Cited by 17
Self-citationDevelopment of a practical biocatalytic process for ( S )- N -Boc-3-hydroxypiperidine synthesis
Chen, L.-F., Fan, H., Zhang, Y., Wu, K., Wang, H., Lin, J., & Wei, D. (2017) · Tetrahedron Letters · doi:10.1016/j.tetlet.2017.03.037 · Cited by 17
Lee, S., Day, N. S., Miles, R. R., Perkins, S. L., Lim, M. S., Ayello, J. S., van de Ven, C., Harrison, L., El‐Mallawany, N. K., Goldman, S. C., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14604 · Cited by 17
Mantle cell lymphoma – Current standards of care and future directions
Martin, P., Ghione, P., & Dreyling, M. H. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.05.008 · Cited by 19
Self-citationAgarwal, R., Dawson, M. A., Dreyling, M. H., & Tam, C. S. L. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1457148 · Cited by 17
Self-citationIbrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia
on behalf of the French Cooperative Group for CLL, S.-T., Michallet, M., Dreger, P., Sobh, M., Köster, L., Hoek, J., Boumendil, A., Scheid, C., Fox, C. P., Wulf, G. G., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0742-7 · Cited by 17
Tsukamoto, T., Nakahata, S., Sato, R., Kanai, A., Nakano, M., Chinen, Y., Maegawa, S., Matsumura‐Kimoto, Y., Takimoto‐Shimomura, T., Mizuno, Y., et al. (2019) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20169 · Cited by 17
Targeted selective degradation of Bruton’s tyrosine kinase by PROTACs
Liu, S., Da, Y., Wang, F., Yan, R., Shu, Y., Lin, P., & Lin, J. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02526-3 · Cited by 17
Castellino, A., Tun, A. M., Wang, Y., Habermann, T. M., King, R. L., Ristow, K. M., Cerhan, J. R., Inwards, D. J., Paludo, J., Ansell, S. M., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-020-00394-z · Cited by 17
Munshi, P. N., Hamadani, M., Kumar, A., Dreger, P., Friedberg, J. W., Dreyling, M. H., Kahl, B. S., Jerkeman, M., Kharfan‐Dabaja, M. A., Locke, F. L., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.03.001 · Cited by 17
Self-citationRare central nervous system lymphomas
Kaji, F. A., Martínez‐Calle, N., Sovani, V., & Fox, C. P. (2022) · British Journal of Haematology · doi:10.1111/bjh.18128 · Cited by 17
CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse
Vu, K., & Frank, M. J. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008031 · Cited by 17
Liposomal amphotericin B—the future
Hoenigl, M., Lewis, R. E., van de Veerdonk, F. L., Verweij, P. E., & Cornely, O. A. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac353 · Cited by 18
Rudelius, M., Rauert‐Wunderlich, H., Hartmann, E., Hoster, E., Dreyling, M. H., Klapper, W., Ott, G., & Rosenwald, A. (2015) · Haematologica · doi:10.3324/haematol.2015.127399 · Cited by 17
Self-citationBroccoli, A., Casadei, B., Morigi, A., Sottotetti, F., Gotti, M., Spina, M., Volpetti, S., Ferrero, S., Spina, F., Pisani, F., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25215 · Cited by 17
C-X-C Chemokine Receptor 4 in Diffuse Large B Cell Lymphoma: Achievements and Challenges
Du, H., Gao, L., Luan, J. Y., Zhang, H., & Xiao, T. (2019) · Acta Haematologica · doi:10.1159/000497430 · Cited by 17
Ibrahim, A. N., Yamashita, D., Anderson, J. C., Abdelrashid, M., Alwakeal, A., Estévez-Ordoñez, D., Komarova, S., Markert, J. M., Goidts, V., Willey, C. D., et al. (2019) · Journal of neurosurgery · doi:10.3171/2019.7.jns191376 · Cited by 17
Cardiovascular Toxicities of Bruton’s Tyrosine Kinase Inhibitors
Pineda-Gayoso, R., Alomar, M., Lee, D. H., & Fradley, M. G. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00764-6 · Cited by 17
Toward New Treatments for Mantle-Cell Lymphoma?
Zucca, E., & Bertoni, F. (2013) · New England Journal of Medicine · doi:10.1056/nejme1307596 · Cited by 17
Meriranta, L., Jørgensen, R. R. K., Pasanen, A., Kolstad, A., Hutchings, M., Niemann, C. U., El‐Galaly, T. C., Riise, J., Christensen, J. H., Sonnevi, K., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025015791 · Cited by 16
Off-Target Effects of Cancer Therapy on Development of Therapy-Induced Arrhythmia: A Review
Leiva, O., Bohart, I., Ahuja, T., & Park, D. S. (2023) · Cardiology · doi:10.1159/000529260 · Cited by 17
Effective Management Strategies for Patients with Marginal Zone Lymphoma
Rosand, C. B., Valla, K., Flowers, C. R., & Koff, J. L. (2017) · Future Oncology · doi:10.2217/fon-2017-0480 · Cited by 16
Romaguera, J. E., Wang, M. L., Feng, L., Fayad, L., Hagemeister, F. B., McLaughlin, P. J., Rodriguez, M. A., Fanale, M. A., Orlowski, R. Z., Kwak, L. W., et al. (2018) · Cancer · doi:10.1002/cncr.31361 · Cited by 16
Self-citationRodgers, T. D., & Reagan, P. M. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1479396 · Cited by 16
Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003
Maaland, A. F., Heyerdahl, H., O’Shea, A., Eiríksdóttir, B., Pascal, V., Andersen, J. T., Kolstad, A., & Dahle, J. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04417-1 · Cited by 16
Pola, R., Pokorná, E., Vočková, P., Böhmová, E., Pechar, M., Karolová, J., Pankrác, J., Šefc, L., Helman, K., Trněný, M., et al. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.11.014 · Cited by 16
Mussetti, A., Devlin, S. M., Castro-Malaspina, H. R., Barker, J. N., Giralt, S., Zelenetz, A. D., Sauter, C. S., & Perales, M.-A. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.156 · Cited by 16
Hagiwara, K., Kunishima, S., Iida, H., Miyata, Y., Naoe, T., & Nagai, H. (2015) · APOPTOSIS · doi:10.1007/s10495-015-1125-1 · Cited by 16
Titus-Rains, K. S., Brown, J. N., & Hammond, J. M. (2017) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217718617 · Cited by 16
Improving the Solubility and Dissolution of Ibrutinib by Preparing Solvates
Shi, X., Song, S., Ding, Z., Fan, B., Xu, T., & Huang, W. Z. (2019) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-019-09402-7 · Cited by 16
Electrophysiology Translational Considerations in Cardio-Oncology: QT and Beyond
Alomar, M., & Fradley, M. G. (2019) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-019-09924-y · Cited by 16
PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR
Jin, J., Wang, L., Tao, Z., Zhang, J., Lv, F., Cao, J., & Hu, X. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11022 · Cited by 16
Yu, H., Truong, H., Mitchell, S. A., Liclican, A. C., Gosink, J. J., Li, W., Lin, J. H., Feng, J. Y., Jürgensmeier, J. M., Billin, A. N., et al. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218786165 · Cited by 15
Mato, A. R., Jauhari, S., & Schuster, S. J. (2015) · American Journal of Hematology · doi:10.1002/ajh.24021 · Cited by 15
Unlocking New Therapeutic Targets and Resistance Mechanisms in Mantle Cell Lymphoma
Colomer, D., & Campo, E. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.011 · Cited by 15
Molecular Evidence for Antigen Drive in the Natural History of Mantle Cell Lymphoma
Xochelli, A., Sutton, L., Agathangelidis, A., Stalika, E., Karypidou, M., Marantidou, F., López, A. N., Papadopoulos, G., Šupíková, J., Groenen, P. J. T. A., et al. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.02.006 · Cited by 15
Ninomoto, J. S., Mokatrin, A., Kinoshita, T., Marimpietri, C., Barrett, T. D., Chang, B. Y., Sukbuntherng, J., James, D. F., & Crowther, M. A. (2020) · Hematology · doi:10.1080/16078454.2020.1730080 · Cited by 15
Self-citationLee, S. M., Wages, N. A., Goodman, K. A., & Lockhart, A. C. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00379 · Cited by 15
Ikaros Proteins in Tumor: Current Perspectives and New Developments
Xia, R., Cheng, Y., Han, X., Wei, Y., & Wei, X. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.788440 · Cited by 17
de Rooij, M. F. M., Thus, Y. J., Swier, N., Beijersbergen, R. L., Pals, S. T., & Spaargaren, M. (2022) · Nature Communications · doi:10.1038/s41467-022-29835-y · Cited by 15
Drug-drug interactions: Implications for anticoagulation, with focus in patients with cancer
Wang, T. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2021.11.026 · Cited by 15
Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders
Maître, E., Paillassa, J., & Troussard, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1068981 · Cited by 15
Ofatumumab in the treatment of non-Hodgkin’s lymphomas
Karlin, L., & Coiffier, B. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1055241 · Cited by 15
Bortezomib in the Treatment of Mantle Cell Lymphoma
Robak, T. (2015) · Future Oncology · doi:10.2217/fon.15.191 · Cited by 15
Smith, M. R., Hong, F., Li, H., Gordon, L. I., Gascoyne, R. D., Paietta, E. M., Advani, R. H., Forero-Torres, A., Horning, S. J., & Kahl, B. S. (2016) · Leukemia · doi:10.1038/leu.2016.305 · Cited by 15
Self-citationHuang, S., Jiang, C., Zhang, H., Bell, T., Guo, H., Liu, Y., Yao, Y., Zeng, D., Ahmed, M., Nomie, K. J., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0066-7 · Cited by 15
Self-citationCurrent trials for frontline therapy of mantle cell lymphoma
Steiner, R. E., Romaguera, J. E., & Wang, M. L. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0556-x · Cited by 15
Self-citationCryptococcus neoformansinfections in patients with lymphoproliferative neoplasms
Dioverti, M. V., Parikh, S. A., Osmon, D. R., Habermann, T. M., & Tande, A. J. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1508666 · Cited by 15
Sawalha, Y., Bond, D. A., & Alinari, L. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s238832 · Cited by 15
Assis‐Mendonça, G. R., Crepaldi, A. H., Delamain, M. T., Moreira, A. H., Costa, F. D., de Lima, V. C. C., Souza, C. A. D., Soares, F. A., & Vassallo, J. (2018) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2018.02.004 · Cited by 14
Pyrazolopyrimidines as attractive pharmacophores in efficient drug design: A recent update
Dorababu, A. (2022) · Archiv der Pharmazie · doi:10.1002/ardp.202200154 · Cited by 14
Chin, L., Kumana, C. R., Kwong, Y., & Gill, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091945 · Cited by 16
Bravo-González, A., Alasfour, M., Soong, D., Noy, J., & Pongas, G. N. (2024) · Cancers · doi:10.3390/cancers16203434 · Cited by 14
Transplantation for mantle cell lymphoma: is it the right thing to do?
Williams, M. E. (2013) · Hematology · doi:10.1182/asheducation-2013.1.568 · Cited by 14
Self-citationThe potential for chemotherapy-free strategies in mantle cell lymphoma
Martin, P., Ruan, J., & Leonard, J. P. (2017) · Blood · doi:10.1182/blood-2017-05-737510 · Cited by 14
Self-citationYu, C.-H., Chou, C., Tu, H.-F., Huang, W.-C., Ho, Y.-Y., Khoo, K., Lee, M., & Chang, G. (2018) · Oncotarget · doi:10.18632/oncotarget.25177 · Cited by 15
Arrhythmogenic Anticancer Drugs in Cardio-Oncology
Rhea, I. B., Burgos, P. H., & Fradley, M. G. (2019) · Cardiology Clinics · doi:10.1016/j.ccl.2019.07.011 · Cited by 14
Ibrutinib’s off-target mechanism: cause for dose optimization
Zimmerman, S. M., Peer, C. J., & Figg, W. D. (2021) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.1980313 · Cited by 14
Jimenez, J. E., Dai, D., Xu, G., Zhao, R., Li, T., Pan, T., Wang, L., Lin, Y., Wang, Z., Jaffray, D. A., et al. (2022) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004060 · Cited by 14
Bruton's TK Inhibitors: Structural Insights and Evolution of Clinical Candidates
Xing, L., & Huang, A. J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.24 · Cited by 14
Management of mantle cell lymphoma in the elderly patient
Kluin‐Nelemans, H. C., & Doorduijn, J. K. (2013) · Clinical Interventions in Aging · doi:10.2147/cia.s35082 · Cited by 14
Optimal disease surveillance strategies in non-Hodgkin lymphoma
Cohen, J. B., & Flowers, C. R. (2014) · Hematology · doi:10.1182/asheducation-2014.1.481 · Cited by 14
Lorková, L., Ščigelová, M., Arrey, T. N., Vít, O., Pospíšilová, J., Doktorova, E., Klánová, M., Alam, M. M., Vočková, P., Maswabi, B. C. L., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135314 · Cited by 14
Puvvada, S. D., Guillen-Rodriguez, J., Kumar, A., Inclán, L., Heard, K., Rivera, X. I., Anwer, F., Schatz, J. H., Mahadevan, D., & Persky, D. O. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.09.001 · Cited by 14
Takimoto‐Shimomura, T., Nagoshi, H., Maegawa, S., Fujibayashi, Y., Tsukamoto, T., Matsumura‐Kimoto, Y., Mizuno, Y., Chinen, Y., Mizutani, S., Shimura, Y., et al. (2018) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20080 · Cited by 14
Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management
Isaac, K. M., Portell, C. A., & Williams, M. E. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01094-y · Cited by 14
Self-citationSaba, N. S., Angelova, M., Lobelle‐Rich, P., & Levy, L. S. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.08.002 · Cited by 14
Recommendations for Clinical Trial Development in Mantle Cell Lymphoma
Spurgeon, S. E. F., Till, B. G., Martin, P., Goy, A. H., Dreyling, M. H., Gopal, A. K., LeBlanc, M. L., Leonard, J. P., Friedberg, J. W., Baizer, L., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw263 · Cited by 13
Self-citationThe shifting therapeutic paradigm for relapsed/refractory mantle cell lymphoma
Kumar, S. A., Gao, J., & Patel, S. A. (2023) · Leukemia Research · doi:10.1016/j.leukres.2023.107385 · Cited by 13
Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study
Samples, L. S., Voutsinas, J. M., Fakhri, B., Khajavian, S., Spurgeon, S. E. F., Stephens, D. M., Skarbnik, A. P. Z., Mato, A. R., Broome, C. M., Gopal, A. K., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011569 · Cited by 13
Self-citationZou, Y., Xiao, J., Tu, Z., Zhang, Y., Yao, K., Luo, M., Ding, K., Zhang, Y., & Lai, Y. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.05.014 · Cited by 13
Implementation of a Model-Based Design in a Phase Ib Study of Combined Targeted Agents
Wages, N. A., Portell, C. A., Williams, M. E., Conaway, M. R., & Petroni, G. R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1069 · Cited by 13
Self-citation
Metadata
- Authors
- Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., Barrientos, J. C., Chmielowska, E., Radford, J., Stilgenbauer, S., Dreyling, M., Jedrzejczak, W. W., Johnson, P., Spurgeon, S. E., Li, L., Zhang, L., Newberry, K., Ou, Z., Cheng, N., Fang, B., McGreivy, J., Clow, F., Buggy, J. J., Chang, B. Y., Beaupre, D. M., Kunkel, L. A., & Blum, K. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Derriford Hospital (GB)
- Weill Cornell Medicine (US)
- Hackensack University Medical Center (US)
- University of Wisconsin–Madison (US)
- Jagiellonian University (PL)
- Stanford Medicine (US)
- University of Virginia (US)
- Northwell Health (US)
- Centrum Onkologii (PL)
- University of Manchester (GB)
- University Hospital Ulm (DE)
- LMU Klinikum (DE)
- Cancer Research UK (GB)
- Oregon Health & Science University (US)
- Pharmacyclics (United States) (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- ORCID
- Wang, Michael L.
- Rule, Simon
- Martin, Peter
- Goy, Andre
- Auer, Rebecca
- Kahl, Brad S.
- Jurczak, Wojciech
- Advani, Ranjana H.
- Romaguera, Jorge E.
- Williams, Michael E.
- Barrientos, Jacqueline C.
- Radford, John
- Stilgenbauer, Stephan
- Dreyling, Martin
- Johnson, Peter
- Spurgeon, Stephen E.
- Li, Lei
- Zhang, Liang
- Newberry, Kate
- Fang, Bingliang
- Chang, Betty Y.
- Blum, Kristie A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-08-08
- Volume
- 369
- Issue
- 6
- Pages
- 507-516
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4513941
- OpenAlex
- W2154066874
- Cited by
- 1,685
- References
- 39
- Citations by year
- 2026: 59 · 2025: 67 · 2024: 91 · 2023: 115 · 2022: 142 · 2021: 127 · 2020: 138 · 2019: 127 · 2018: 141 · 2017: 161 · 2016: 133 · 2015: 189 · 2014: 147 · 2013: 42
- FWCI
- 127.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Funders
- American Society of Hematology
- Amgen
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Gilead Sciences
- Celgene
- Massachusetts Medical Society
- Les Laboratories Pierre Fabre
- Genentech
- Pharmacyclics
- National Cancer Institute (P30CA014520)
- Janssen Biotech
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
- Keywords
- ibrutinib, BTK inhibitors, mantle cell lymphoma, relapsed/refractory lymphoma, bortezomib, B cell receptor signaling, oral BTK inhibitor, overall response rate, progression-free survival, overall survival, adverse events, neutropenia
- MeSH terms
- Agammaglobulinaemia Tyrosine Kinase, Adenine, Administration, Oral, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Recurrence, Survival Analysis, Lymphocyte Count, Drug Resistance, Neoplasm, Lymphoma, Mantle-Cell, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
